Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences, Millipore Ink Alzheimer's Assay Deal

NEW YORK (GenomeWeb News) – Proteome Sciences and Millipore jointly announced today that they will collaborate on the development of multiplex immunoassays for Alzheimer's disease research.

Under terms of the deal, Millipore will develop the immunoassays on the Luminex platform to measure Proteome Sciences' Alzheimer's disease biomarkers. Billerica, Mass.-based Millipore will have exclusive rights to develop and sell Luminex bead-based panels for Alzheimer's research as well as other cognitive function disorders.

Cobham, UK-based Proteome Sciences retains all rights to clinical applications of the biomarkers. The firm has identified these biomarkers through a collaboration with the Institute of Psychiatry at Kings College, London.

"By expanding our portfolio of multiplex immunoassays targeting Alzheimer's disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits."

Financial terms of the alliance were not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.